---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-005107"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T03:28:21.040701+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Anika Q2 revenue rises 12% to $44.3M; raises FY2023 guidance floor to $159.5M

## Summary
- Q2 revenue $44.3M (+12% YoY); net loss ($0.19)/share; adjusted EPS $0.06 vs ($0.12) prior year.
- OA Pain Mgmt rev +22% to $29.3M; Joint Preservation & Restoration +5% to $12.7M.
- FY2023 rev guidance raised: $159.5M-$163M (was $158M-$163M), representing 2-4% growth.
- Hyalofast Phase III fully enrolled; PMA submission begins 2024; Cingal ongoing FDA discussions after Type-C meeting.
- RevoMotion reverse shoulder full market launch accelerated to Sept 2023; Integrity rotator cuff patch 2024 launch on track.

## SEC filing metadata
- accession: 0001171843-23-005107
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184323005107/0001171843-23-005107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184323005107/f8k_080823.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-005107
- JSON: https://secwatch.observer/filing/0001171843-23-005107.json
- Plain text: https://secwatch.observer/filing/0001171843-23-005107.txt

## Key facts
- Earnings Releases
  Anika Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $44.3 million, net income ($2.7) million, or ($0.19) per share, EPS ($0.19) per share. Guidance raised.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $44.3 million
  - Net income: ($2.7) million, or ($0.19) per share
  - EPS: ($0.19) per share
  - Guidance: raised
  - Result: reported results
  source text: Revenue in the second quarter of 2023 was $44.3 million, up 12% compared to $39.7 million in the second quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184323005107/0001171843-23-005107-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.